Passage Historical Financial Ratios
| PASG Stock | USD 0.50 0.02 4.17% |
Passage Bio is promptly reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 0.96, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.0 will help investors to properly organize and evaluate Passage Bio financial condition quickly.
Passage |
About Passage Financial Ratios Analysis
Passage BioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Passage Bio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Passage financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Passage Bio history.
Passage Bio Financial Ratios Chart
Add Fundamental
Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Most ratios from Passage Bio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Passage Bio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.At this time, Passage Bio's Payables Turnover is most likely to increase slightly in the upcoming years. The Passage Bio's current Income Quality is estimated to increase to 0.96, while Free Cash Flow Yield is projected to decrease to (1.47).
Passage Bio fundamentals Correlations
Click cells to compare fundamentals
Passage Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Passage Bio fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 3.24 | 1.06 | 0.37 | 0.5 | 0.56 | 0.59 | |
| Book Value Per Share | 7.89 | 5.97 | 3.7 | 2.03 | 1.01 | 0.96 | |
| Free Cash Flow Yield | (0.0832) | (0.45) | (1.64) | (1.42) | (1.4) | (1.47) | |
| Operating Cash Flow Per Share | (2.09) | (2.38) | (2.17) | (1.43) | (0.79) | (0.83) | |
| Capex To Depreciation | 2.06 | 16.62 | 1.43 | 0.0392 | 0.011 | 0.0105 | |
| Pb Ratio | 3.24 | 1.06 | 0.37 | 0.5 | 0.56 | 0.59 | |
| Free Cash Flow Per Share | (2.13) | (2.86) | (2.27) | (1.43) | (0.79) | (0.83) | |
| Roic | (0.37) | (0.59) | (0.6) | (0.79) | (0.81) | (0.85) | |
| Net Income Per Share | (2.89) | (3.59) | (2.51) | (1.86) | (1.07) | (1.13) | |
| Payables Turnover | 0.15 | 0.16 | 0.91 | 2.87 | 2.58 | 2.71 | |
| Cash Per Share | 7.89 | 5.92 | 3.48 | 2.09 | 1.27 | 1.21 | |
| Pocfratio | (25.48) | (12.26) | (2.67) | (0.64) | (0.71) | (0.75) | |
| Capex To Operating Cash Flow | (0.0204) | (0.2) | (0.0446) | (0.001865) | (7.09E-4) | (7.44E-4) | |
| Pfcf Ratio | (24.45) | (12.02) | (2.22) | (0.61) | (0.71) | (0.75) | |
| Days Payables Outstanding | 2.4K | 2.2K | 403.3 | 127.32 | 146.42 | 139.1 | |
| Income Quality | 0.87 | 0.72 | 0.68 | 0.77 | 0.74 | 0.96 | |
| Roe | (0.37) | (0.6) | (0.68) | (0.92) | (1.06) | (1.0) | |
| Ev To Operating Cash Flow | (10.59) | (1.65) | (0.57) | (0.77) | (0.46) | (0.49) | |
| Pe Ratio | (8.83) | (1.77) | (0.55) | (0.54) | (0.53) | (0.56) | |
| Return On Tangible Assets | (0.34) | (0.54) | (0.56) | (0.68) | (0.63) | (0.66) | |
| Ev To Free Cash Flow | (10.37) | (1.38) | (0.55) | (0.76) | (0.46) | (0.48) | |
| Earnings Yield | (0.11) | (0.57) | (1.82) | (1.85) | (1.89) | (1.99) | |
| Net Debt To E B I T D A | 1.2 | 0.69 | 0.0541 | (0.0466) | 0.17 | 0.16 | |
| Current Ratio | 14.98 | 11.02 | 10.74 | 7.22 | 4.07 | 3.87 | |
| Tangible Book Value Per Share | 7.89 | 5.97 | 3.7 | 2.03 | 1.01 | 0.96 | |
| Shareholders Equity Per Share | 7.89 | 5.97 | 3.7 | 2.03 | 1.01 | 0.96 | |
| Capex Per Share | 0.0426 | 0.48 | 0.0969 | 0.002667 | 5.63E-4 | 5.35E-4 | |
| Graham Net Net | 7.29 | 5.24 | 2.71 | 1.37 | 0.59 | 0.56 | |
| Enterprise Value Over E B I T D A | (7.55) | (1.13) | (0.49) | (0.61) | (0.31) | (0.33) | |
| Price Earnings Ratio | (8.83) | (1.77) | (0.55) | (0.54) | (0.53) | (0.56) | |
| Price Book Value Ratio | 3.24 | 1.06 | 0.37 | 0.5 | 0.56 | 0.59 | |
| Price Earnings To Growth Ratio | (0.0618) | (0.073) | 0.0182 | 0.0209 | 0.0125 | 0.0131 | |
| Days Of Payables Outstanding | 2.4K | 2.2K | 403.3 | 127.32 | 146.42 | 139.1 | |
| Price To Operating Cash Flows Ratio | (25.48) | (12.26) | (2.67) | (0.64) | (0.71) | (0.75) | |
| Price To Free Cash Flows Ratio | (24.45) | (12.02) | (2.22) | (0.61) | (0.71) | (0.75) | |
| Ebt Per Ebit | 0.99 | 1.0 | 0.98 | 0.94 | 0.92 | 1.1 | |
| Effective Tax Rate | (0.2) | 0.004188 | (0.033) | (0.00537) | (0.004833) | (0.005075) | |
| Company Equity Multiplier | 1.08 | 1.11 | 1.21 | 1.35 | 1.67 | 1.76 | |
| Return On Capital Employed | (0.37) | (0.57) | (0.61) | (0.81) | (0.85) | (0.89) | |
| Quick Ratio | 14.98 | 11.02 | 10.74 | 7.22 | 4.07 | 3.87 |
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.